Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2023; 29(3): 579-581
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.579
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.579
Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
Jun-Hao Huang, Wei Guo, Zhe Liu, Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Huang JH and Guo W wrote the manuscript; Liu Z edited the manuscript; and all authors have read and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhe Liu, MD, Doctor, Professor, Surgeon, Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. liuzhe4321@126.com
Received: October 28, 2022
Peer-review started: October 28, 2022
First decision: November 30, 2022
Revised: December 12, 2022
Accepted: January 3, 2023
Article in press: January 3, 2023
Published online: January 21, 2023
Processing time: 76 Days and 9.2 Hours
Peer-review started: October 28, 2022
First decision: November 30, 2022
Revised: December 12, 2022
Accepted: January 3, 2023
Article in press: January 3, 2023
Published online: January 21, 2023
Processing time: 76 Days and 9.2 Hours
Core Tip
Core Tip: In terms of the choice of chemotherapy regimen for pancreatic cancer, multi-drug chemotherapy is often applied in clinical practice. In general, the combination of chemotherapy and targeted therapy have better efficacy, but whether the combination of the two schemes is more effective than chemotherapy alone requires further investigations.